<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> people and diabetic patients are known to be high risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), suggesting need of a new preclinical animal model, by which to extensively study the diverse mechanisms, therapy and prevention </plain></SENT>
<SENT sid="1" pm="."><plain>The present study aimed to determine whether experimental <z:mp ids='MP_0001261'>obese</z:mp> and diabetic mice produced by monosodium <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> (MSG) treatment are susceptible to azoxymethane (AOM)-induced colon <z:mp ids='MP_0002006'>tumorigenesis</z:mp> using early biomarkers, <z:mpath ids='MPATH_557'>aberrant crypts foci</z:mpath> (ACF) and β-catenin-accumulated crypts (BCACs), of colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Male Crj:CD-1 (ICR) newborns were daily given four subcutaneous injections of MSG (2 mg/g body wt) to induce <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>They were then given four intraperitoneal injections of AOM (15 mg/kg body wt) or saline (0.1 ml saline/10 g body wt) </plain></SENT>
<SENT sid="4" pm="."><plain>Ten weeks after the last injection of AOM, the MSG-AOM mice had a significant increase in the multiplicity of BCAC (13.83 ± 7.44, P &lt; 0.002), but not ACF (78.00 ± 11.20), when compare to the Saline-AOM mice (5.45 ± 1.86 of BCAC and 69.27 ± 8.06 of ACF) </plain></SENT>
<SENT sid="5" pm="."><plain>Serum biochemical profile of the MSG-treated mice with or without AOM showed <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo>, <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesteremia</z:e> and <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of insulin-like growth factor-1 receptor (IGF-1R, P&lt;0.01) was increased in the MSG-AOM mice, when compared with the mice given AOM alone </plain></SENT>
<SENT sid="7" pm="."><plain>IGF-1R was immunohistochemically expressed in the BCAC, but not ACF, in the AOM-treated mice </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings suggest that the MSG mice are highly susceptible to AOM-induced colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, suggesting potential utility of our MSG-AOM mice for further investigation of the possible underlying events that affect the positive association between <z:mp ids='MP_0001261'>obese</z:mp>/<z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>